

Op 1614  
**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Alan M. Warshawsky, et al.**

Examiner:

Serial No.: **08/893,080**

Art Unit: 1205

Filed: **July 15, 1997**

Title: **3-Mercaptoacetylamino-1,5-Substituted--  
Oxo-Azepan Derivatives Useful as  
Inhibitors of Matrix Metalloproteinase**

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as First  
Class Mail in an envelope addressed to Assistant  
Commissioner for Patents, Washington, D.C. 20231, on

Date of Deposit

Signature

*Sept. 1, 1998*  
*Pat Hysell*

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

SEP 11 1998

MAIL ROOM  
SERVICE CENTER

Sir:


Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 13-2764.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

A form PTO 1449 (modified) is attached.


Respectfully submitted,



David M. Stemerick, Reg. No. 40,187  
Attorney/Agent for Applicant

Hoechst Marion Roussel, Inc.  
2110 East Galbraith Road  
P. O. Box 156300  
Cincinnati, Ohio 45215-6300  
Telephone (513) 948-7529  
Telefax (513) 948-7961  
(513) 948-4681

FORM PTO-1449 (Modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)	ATTY. DOCKET NO. <b>M01846A</b>	SERIAL NO. <b>08/893,080</b>
	APPLICANT <b>Alan M. Warshawsky, et al.</b>	
	FILING DATE <b>7-15-97</b>	GROUP <b>1205</b>



## U.S. PATENT DOCUMENTS

EXAMINER INITIALS	*		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	*		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
		B.15	9	6	0	6	8	9	0	9/88	WO			YES	NO
		B.16	9	6	1	1	2	0	9	4/96	WO				
		B.17	9	6	2	9	3	1	3	9/96	WO				

## OTHER DOCUMENTS

EXAMINER INITIALS	*		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.											
		C.30	Derwent Abstract 96-035866, Week 9604, WPI Database XP 002046217											
		C.31	Burkholder, E.A., Bioorg Med Chem Lett, vol 3, no 2, 1993, p 231-234, XP002046216											

EXAMINER	DATE CONSIDERED
<p><b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> <p><b>Not :</b> Ast risk (*) item(s) hav been pr viously cited in a r lated application(s) lth r by th applicant or by th USPTO and th refor copies of th r ferenc (s) ar not being submitted.</p>	